Research Triangle Park, N.C., United States:
For the second consecutive year, Quintiles has been named Best Clinical
Research Organization (CRO) in the Vaccine Industry Excellence (ViE)
Awards. Presented at the World Vaccine Congress now under way in
Washington, D.C., the awards recognize and celebrate individuals,
organizations and initiatives which have made significant contributions
over the past 12 months.
The Best CRO award is presented to the honored CRO following two rounds
of evaluation. First, customers vote for their preferred CRO online
prior to the World Vaccine Congress to arrive at a list of five
companies per category. Then, a judging panel makes its selection based
on information provided in the following criteria:
Range of services provided in niche and core therapeutic areas;
Methods of performance improvement or introduction of new services;
Attention to and quality of relationships with clients;
Reaching of milestones and final/ongoing outcomes; and
Building and maintaining existing and long-term partnerships.
“We’re proud to be recognized by our customers and peers as the Best
CRO,” said Dr. Christopher Cabell, senior vice president, Therapeutic
Delivery Unit. “We work every day to advance the development of quality
vaccines and anti-infective products. This achievement celebrates our
commitment to create a healthier world.”
Two Quintiles scientific and operational experts presented as part of
the technical seminars offered at the World Vaccine Congress.
Nancy Dreyer, global chief of scientific affairs, Quintiles Outcome
presented the need for big data to protect the public from flu
outbreaks, and as a means for overcoming the ongoing challenge of
Vicky Leamy, therapeutic strategy lead, Quintiles Infectious Diseases
and Vaccines, focused on the challenges of large-scale vaccine trials
and the importance of planning to ensure coordination of efforts,
establishing realistic expectations and regional considerations.
Quintiles helped develop or commercialize 73% (11 of 15) of 2011’s
best-selling Vaccine products or compounds.
Quintiles is the world’s largest provider of biopharmaceutical
development and commercial outsourcing services with a network of more
than 27,000 employees conducting business in approximately 100
countries. We have helped develop or commercialize all of the top-50
best-selling drugs on the market. Quintiles applies the breadth and
depth of our service offerings along with extensive therapeutic,
scientific and analytics expertise to help our customers navigate an
increasingly complex healthcare environment as they seek to improve
efficiency and effectiveness in the delivery of better healthcare
to subscribe to Mobile Alerts for Quintiles.
Karl Deonanan, +1-919-998-2789